Radiodermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Radiodermatitis is an inflammation of the skin caused by radiation. The Radiodermatitis pipeline market research report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects.
Radiodermatitis Pipeline Products Market Segmentation by Targets
The key targets in the Radiodermatitis pipeline products market are Adenosine Receptor A2a, Aldehyde Dehydrogenase Mitochondrial, Endothelial PAS Domain Containing Protein 1, Histone Deacetylase, Hypoxia Inducible Factor 1 Alpha, Interleukin 1 Beta, Interleukin 10, Prostaglandin G/H Synthase 2, Serine/Threonine Protein Kinase B Raf, and Tumor Necrosis Factor.
Radiodermatitis Pipeline Products Market Analysis by Targets
For more target insights into the Radiodermatitis pipeline products market, download a free report sample
Radiodermatitis Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Radiodermatitis pipeline products market are Adenosine Receptor A2a Antagonist, Aldehyde Dehydrogenase Mitochondrial Activator, Endothelial PAS Domain Containing Protein 1 Inhibitor, Histone Deacetylase Inhibitor, Hypoxia Inducible Factor 1 Alpha Inhibitor, Interleukin 1 Beta Inhibitor, Interleukin 10 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, and Tumor Necrosis Factor Inhibitor.
Radiodermatitis Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Radiodermatitis pipeline products market, download a free report sample
Radiodermatitis Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Radiodermatitis pipeline products market are topical, oral, intravenous, ophthalmic, rectal, transdermal, buccal, cutaneous, inhalational, and intraocular, among others. Topical leads the Radiodermatitis pipeline products market in terms of RoA.
Radiodermatitis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Radiodermatitis pipeline products market, download a free report sample
Radiodermatitis Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Radiodermatitis pipeline products market are small molecule, biologic, protein, and recombinant protein. Small molecule leads the Radiodermatitis pipeline products market in terms of molecule type.
Radiodermatitis Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Radiodermatitis pipeline products market, download a free report sample
Radiodermatitis Pipeline Products Market - Competitive Landscape
Some of the leading companies in the Radiodermatitis pipeline products market are BioCurity Pharmaceuticals Inc, VasoDynamics Ltd, Allander Biotechnologies LLC, Amryt Pharma Plc, Clevexel Pharma SA, Devonian Health Group Inc, Enveric Biosciences Inc, Foresee Pharmaceuticals Co Ltd, Lutris Pharma, and Matrix Biomed Inc. BioCurity Pharmaceuticals Inc is the leading company in the Radiodermatitis pipeline products market.
Radiodermatitis Pipeline Products Market Analysis by Companies
To know more about the leading players in the Radiodermatitis pipeline products market, download a free report sample
Radiodermatitis Pipeline Products Market Report Overview
| Key Targets | Adenosine Receptor A2a, Aldehyde Dehydrogenase Mitochondrial, Endothelial PAS Domain Containing Protein 1, Histone Deacetylase, Hypoxia Inducible Factor 1 Alpha, Interleukin 1 Beta, Interleukin 10, Prostaglandin G/H Synthase 2, Serine/Threonine Protein Kinase B Raf, and Tumor Necrosis Factor |
| Key Mechanisms of Action | Adenosine Receptor A2a Antagonist, Aldehyde Dehydrogenase Mitochondrial Activator, Endothelial PAS Domain Containing Protein 1 Inhibitor, Histone Deacetylase Inhibitor, Hypoxia Inducible Factor 1 Alpha Inhibitor, Interleukin 1 Beta Inhibitor, Interleukin 10 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, and Tumor Necrosis Factor Inhibitor |
| Key Routes of Administration | Topical, Oral, Intravenous, Ophthalmic, Rectal, Transdermal, Buccal, Cutaneous, Inhalational, and Intraocular |
| Key Molecule Type | Small Molecule, Biologic, Protein, and Recombinant Protein |
| Leading Companies | BioCurity Pharmaceuticals Inc, VasoDynamics Ltd, Allander Biotechnologies LLC, Amryt Pharma Plc, Clevexel Pharma SA, Devonian Health Group Inc, Enveric Biosciences Inc, Foresee Pharmaceuticals Co Ltd, Lutris Pharma, and Matrix Biomed Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key targets in the Radiodermatitis pipeline products market are Adenosine Receptor A2a, Aldehyde Dehydrogenase Mitochondrial, Endothelial PAS Domain Containing Protein 1, Histone Deacetylase, Hypoxia Inducible Factor 1 Alpha, Interleukin 1 Beta, Interleukin 10, Prostaglandin G/H Synthase 2, Serine/Threonine Protein Kinase B Raf, and Tumor Necrosis Factor.
The key mechanisms of action in the Radiodermatitis pipeline products market are Adenosine Receptor A2a Antagonist, Aldehyde Dehydrogenase Mitochondrial Activator, Endothelial PAS Domain Containing Protein 1 Inhibitor, Histone Deacetylase Inhibitor, Hypoxia Inducible Factor 1 Alpha Inhibitor, Interleukin 1 Beta Inhibitor, Interleukin 10 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, and Tumor Necrosis Factor Inhibitor.
The key routes of administration in the Radiodermatitis pipeline products market are topical, oral, intravenous, ophthalmic, rectal, transdermal, buccal, cutaneous, inhalational, and intraocular, among others.
The key molecule types in the Radiodermatitis pipeline products market are small molecule, biologic, protein, and recombinant protein.
Some of the leading companies in the Radiodermatitis pipeline products market are BioCurity Pharmaceuticals Inc, VasoDynamics Ltd, Allander Biotechnologies LLC, Amryt Pharma Plc, Clevexel Pharma SA, Devonian Health Group Inc, Enveric Biosciences Inc, Foresee Pharmaceuticals Co Ltd, Lutris Pharma, and Matrix Biomed Inc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.